Explore a next step for moderate to severe endometriosis pain relief

The first FDA-approved oral treatment for moderate to severe endometriosis pain in over a decade1

See how ORILISSA works

Learn about the GnRH receptor
antagonist mechanism of
action (MOA).1

Available in two oral dosages:

150 mg QD   200 mg BID

Choose the option most appropriate for her based on severity of symptoms and treatment objectives.1

Dyspareunia Non-menstrual pelvic pain Dysmenorrhea